Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease

Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes

(2020) Akira Mima et al.   Scientific Reports

Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories – Insights from the EMPA‐REG OUTCOME trial

(2020) Christoph Wanner et al.   DIABETES OBESITY & METABOLISM

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

(2020) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

(2020) Faiez Zannad et al.   LANCET

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease

(2018) Akira Mima   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

(2018) David Z.I. Cherney et al.   KIDNEY INTERNATIONAL

Obesity-associated glomerular inflammation increases albuminuria without renal histological changes

(2018) Akira Mima et al.   FEBS Open Bio

Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories

(2018) Kyle J Foreman et al.   LANCET

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury

(2017) Beom Jin Lim et al.   KIDNEY INTERNATIONAL

Role of biomechanical forces in hyperfiltration-mediated glomerular injury in congenital anomalies of the kidney and urinary tract

(2017) Tarak Srivastava et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Single-Nephron Glomerular Filtration Rate in Healthy Adults

(2017) Aleksandar Denic et al.   NEW ENGLAND JOURNAL OF MEDICINE

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

(2016) Linda A. Gallo et al.   Scientific Reports

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition

(2015) S. P. Rajeev et al.   DIABETES OBESITY & METABOLISM

Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats

(2015) Kazi Rafiq et al.   DIABETOLOGIA

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats

(2015) Takahiro Oguma et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal Autoregulation in Health and Disease

(2015) Mattias Carlström et al.   PHYSIOLOGICAL REVIEWS

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

(2014) Marko Škrtić et al.   DIABETOLOGIA

A Potential Role for Mechanical Forces in the Detachment of Podocytes and the Progression of CKD

(2014) W. Kriz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Multitarget Stool DNA Testing for Colorectal-Cancer Screening

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Induction of Vascular Insulin Resistance and Endothelin-1 Expression and Acceleration of Atherosclerosis by the Overexpression of Protein Kinase C-β Isoform in the Endothelium

(2013) Qian Li et al.   CIRCULATION RESEARCH

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

(2013) Brian Zambrowicz et al.   CLINICAL THERAPEUTICS

Novel Biomarkers for the Progression of Diabetic Nephropathy: Soluble TNF Receptors

(2013) Tomohito Gohda et al.   Current Diabetes Reports

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans

(2013) M. A. Abdul-Ghani et al.   DIABETES

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Fluid flow shear stress over podocytes is increased in the solitary kidney

(2013) Tarak Srivastava et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

(2013) Harold E. Bays et al.   Obesity

Inflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition as New Therapeutic Targets

(2013) Akira Mima   Journal of Diabetes Research

Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC  Activation in Diabetes

(2012) A. Mima et al.   DIABETES

Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?

(2012) J. Liu et al.   DIABETES

Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes

(2012) T. Gohda et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Suppression of Oxidative Stress by  -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor

(2012) T. Shimazu et al.   SCIENCE

The Challenge and Response of Podocytes to Glomerular Hypertension

(2012) Nicole Endlich et al.   SEMINARS IN NEPHROLOGY

Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice

(2011) Nariaki Asada et al.   JOURNAL OF CLINICAL INVESTIGATION

Glomerular-specific protein kinase C-β-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity

(2011) Akira Mima et al.   KIDNEY INTERNATIONAL

Activation of Src Mediates PDGF-Induced Smad1 Phosphorylation and Contributes to the Progression of Glomerulosclerosis in Glomerulonephritis

(2011) Akira Mima et al.   PLoS One

Heart Rate Variability Predicts ESRD and CKD-Related Hospitalization

(2010) D. J. Brotman et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE